BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25522951)

  • 21. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
    Chen X; Wang X; Wei X; Wang J
    J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L1 (CAM) (CD171) in ovarian serous neoplasms.
    Daponte A; Kostopoulou E; Kollia P; Papamichali R; Vanakara P; Hadjichristodoulou C; Nakou M; Samara S; Koukoulis G; Messinis IE
    Eur J Gynaecol Oncol; 2008; 29(1):26-30. PubMed ID: 18386459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of extracellular matrix proteins in ovarian serous tumors.
    Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
    Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Serous and non-serous ovarian carcinoma: histological tumor type as related to the grade of differentiation and disease prognosis].
    Ferreira PA; Sallum LF; Sarian LO; Andrade LA; Derchain S
    Rev Bras Ginecol Obstet; 2012 May; 34(5):196-202. PubMed ID: 22584853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
    Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
    Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D
    Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
    Zhao S; Dorn J; Napieralski R; Walch A; Diersch S; Kotzsch M; Ahmed N; Hooper JD; Kiechle M; Schmitt M; Magdolen V
    Biol Chem; 2017 Jun; 398(7):765-773. PubMed ID: 27935848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.
    Kriegsmann K; Zgorzelski C; Muley T; Christopoulos P; Thomas M; Winter H; Eichhorn M; Eichhorn F; von Winterfeld M; Herpel E; Goeppert B; Stenzinger A; Herth FJF; Warth A; Kriegsmann M
    BMC Cancer; 2021 May; 21(1):486. PubMed ID: 33933015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
    Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
    Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical significance of neuroendocrine differentiation in T3-T4 node-negative colorectal cancer.
    Cho YB; Yang SS; Lee WY; Song SY; Kim SH; Shin HJ; Yun SH; Chun HK
    Int J Surg Pathol; 2010 Jun; 18(3):201-6. PubMed ID: 19372085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of Nestin and CD133 in serous ovarian carcinoma.
    Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
    J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian neuroendocrine carcinoma of metastatic origin: clues for diagnosis.
    Karpathiou G; Matias-Guiu X; Mobarki M; Vermesch C; Stachowicz ML; Chauleur C; Peoc'h M
    Hum Pathol; 2019 Mar; 85():309-312. PubMed ID: 30171991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary.
    Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Janssen EA; Baak JP; Rollason TP
    Int J Gynecol Pathol; 2008 Apr; 27(2):191-8. PubMed ID: 18317224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Sehouli J; Kunze CA; Dietel M; Braicu I; Letsch A; Darb-Esfahani S
    Gynecol Oncol; 2016 Mar; 140(3):494-502. PubMed ID: 26721227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
    Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
    Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.
    Crane LM; Arts HJ; van Oosten M; Low PS; van der Zee AG; van Dam GM; Bart J
    Cell Oncol (Dordr); 2012 Feb; 35(1):9-18. PubMed ID: 21647742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma.
    Arts FA; Keogh L; Smyth P; O'Toole S; Ta R; Gleeson N; O'Leary JJ; Flavin R; Sheils O
    Hum Pathol; 2017 Dec; 70():98-104. PubMed ID: 29079174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.